Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study

1

This phase II study evaluated the efficacy and safety of DCF-based chemoradiotherapy for postoperative locoregional recurrence of esophageal cancer.
2

The trial included 29 patients who received 60 Gy of radiotherapy with concurrent docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
3

The median progression-free survival was 48.0 months, significantly exceeding the historical control of 12 months.
4

Three-year and five-year overall survival rates were 75.2% and 58.8%, respectively, indicating favorable long-term outcomes.
5

The treatment demonstrated a high compliance rate, with 89.7% of patients completing the regimen without dose reduction.

Frontiers In Oncology

by Keiichi Jingu, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Masanobu Takahashi, Takashi Kamei, Haruo Matsushita
July 9, 2026

1